Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Guttman-Yassky, Emma [1 ]
Weidinger, Stephan [2 ]
Simpson, Eric [3 ]
Gooderham, Melinda [4 ,5 ]
Irvine, Alan [6 ]
Spelman, Lynda [7 ,8 ]
Silverberg, Jonathan [9 ]
Elmaraghy, Hany [10 ]
DeLuca-Carter, Louise [10 ]
Piruzeli, Maria Lucia Buziqui [10 ]
Hu, Chaoran [10 ]
Yang, Fan Emily [10 ]
Pierce, Evangeline [10 ]
Bardolet, Laia [11 ]
Thaci, Diamant [12 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Prob Med Res, SKiN Dermatol, Peterborough, ON, Canada
[5] Queens Univ, Peterborough, ON, Canada
[6] Childrens Hlth Ireland, Dublin, Ireland
[7] Verac Clin Res, Woolloongabba, Qld, Australia
[8] Prob Med Res, Woolloongabba, Qld, Australia
[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA
[10] Eli Lilly & Co, Indianapolis, IN 46285 USA
[11] Almirall SA, Barcelona, Spain
[12] Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
atopic dermatitis; efficacy; lebrikizumab; phase; 3; trials; safety;
D O I：
10.1093/bjd/ljad498.005
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
494
引用
收藏
页码：II3 / II4
页数：2
相关论文
共 50 条
  • [1] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Smith, Brandon I.
    Engel, Priya
    Wu, Jashin
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
  • [2] Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
    Diana Bernardo
    Thomas Bieber
    Tiago Torres
    American Journal of Clinical Dermatology, 2023, 24 : 753 - 764
  • [3] Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
    Bernardo, Diana
    Bieber, Thomas
    Torres, Tiago
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 753 - 764
  • [4] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan D.
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 61
  • [5] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Pinto-Correia, Ana
    Natalie, Chitra R.
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    Isho, Nadine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [6] Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study
    Paller, Amy
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Irvine, Alan
    Correia, Ana Pinto
    Natalie, Chitra R.
    Pierce, Evangeline
    Lima, Renata Gontijo
    Laquer, Vivian
    Weidinger, Stephan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB84 - AB84
  • [7] MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH STABLE ASTHMA CONTROL
    Mehta, V.
    Worm, M.
    Chiesa, Z.
    Natalie, C.
    Dawson, Z.
    Zhong, J.
    Diemert, S.
    Boguniewicz, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S89 - S90
  • [8] Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age
    Armstrong, April
    Zirwas, Matthew
    Napolitano, Maddalena
    Torres, Tiago
    Staumont-Salle, Delphine
    Atwater, Amber Reck
    Dossenbach, Martin
    Agell, Helena
    Chen, Sherry
    Qiao, Meihua
    Pierce, Evangeline
    Piruzeli, Maria Lucia Buziqui
    Mostaghimi, Arash
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [9] Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan D.
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing
    Lima, Renata Gontijo
    Pillai, Sreekumar G.
    Seneschal, Julien
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (12): : 1080 - 1091
  • [10] Efficacy and safety of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
    Lin, Jinger
    Luo, Min
    Zhuo, Qianwei
    Chen, Nuo
    Zhang, Haosong
    Han, Yue
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345